Case Summary:   

We are proud to announce the EB2-NIW (National Interest Waiver) approval of a dedicated neuroscientist from Nepal whose pioneering work is shedding light on the brain’s mechanisms for pain regulation and opening the door to transformative gene therapies. Through a highly original line of research into animal motivation and neural circuitry, this scientist is contributing vital knowledge that may one day lead to novel treatments for chronic pain and its associated disorders.

Aiming for Precision in Pain Management

The client’s research centers on understanding the cellular and molecular mechanisms that govern pain perception and relief. By studying specific brain circuits and epigenetic pathways in animal models, they aim to develop targeted gene therapies that can address the root causes of pain, rather than simply masking symptoms.

Their current role as a research associate in the U.S. supports investigations into blood cancer mechanisms and neural control of breast cancer progression. Yet their broader scientific vision remains focused on unlocking genetic and circuit-level solutions to persistent pain conditions, contributing to one of the most pressing public health concerns in the United States.

High-Impact Publications in Critical Fields

With a publication record that includes 4 peer-reviewed journal articles, including one first-authored, and 15 citations, the client has made notable contributions to both neuroscience and molecular genetics. Several of their works appear in PLOS ONE, ranked among the top 10 journals in life and medical sciences.

Noteworthy research projects include:

● Identification of circular RNAs (circRNAs) from imprinted genes like Peg3 and Igf2r, revealing their roles in disease pathways and gene regulation.

● Clarification of PEG3’s role in lipid synthesis and tumor progression, opening therapeutic possibilities for obesity-related cancers.

● Exploration of allele-specific enhancer dynamics in gene expression, improving understanding of epigenetic control in developmental biology.

National and International Scientific Recognition

Letters from respected experts highlight the significance of the client’s findings. As noted by a professor at a University:

“[Client’s] research is of critical importance in improving healthcare outcomes… His studies of circPeg3 and circIgf2r advance our understanding of tumorigenesis and gene function, and his novel work supports improved healthcare outcomes through enhanced gene-level treatment options.”

The client’s research has been cited by scientists worldwide in fields including neuroscience, genomics, and oncology, and has directly informed further studies in gene regulation, lipid metabolism, and epigenetic control in disease states.

Tackling a Growing Public Health Crisis

Chronic pain affects more than 51 million Americans, imposing an annual economic burden exceeding $500 billion. The client’s work aims to develop next-generation gene therapies that can offer more effective, longer-lasting, and personalized treatment pathways. By targeting specific circuits and regulators of pain and motivation, their research responds directly to a national demand for safer and more sustainable alternatives to opioids and invasive procedures.

A Well-Deserved and Timely Approval

Filed on June 13, 2024, and approved on May 13, 2025, the EB2-NIW petition presented clear evidence of scientific innovation, national relevance, and exceptional qualifications. The swift adjudication reflects the petition’s strength and the pressing importance of the client’s contributions.

We are honored to support visionary scientists whose work has the potential to transform lives. This client’s research on pain biology and gene regulation exemplifies how fundamental science can drive clinical innovation, creating hope for millions and strengthening the future of public health.